Daina Graybosch
Stock Analyst at Leerink Partners
(1.31)
# 3,673
Out of 5,150 analysts
99
Total ratings
42.65%
Success rate
-6.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Market Perform | $115 | $114.30 | +0.61% | 6 | Feb 24, 2026 | |
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.43 | -17.70% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.63 | +22.70% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.54 | +267.24% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.93 | +138.91% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $15.38 | -21.98% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $120.28 | -1.06% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.46 | +348.43% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $71.11 | -36.72% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.45 | +589.66% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $22.68 | +67.55% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $5.11 | +56.56% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $103.80 | +115.80% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.73 | +998.90% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.61 | +2,675.51% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.14 | +320.56% | 4 | Feb 25, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Market Perform
Price Target: $115
Current: $114.30
Upside: +0.61%
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.43
Upside: -17.70%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.63
Upside: +22.70%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.54
Upside: +267.24%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.93
Upside: +138.91%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $15.38
Upside: -21.98%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $120.28
Upside: -1.06%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.46
Upside: +348.43%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $71.11
Upside: -36.72%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.45
Upside: +589.66%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $22.68
Upside: +67.55%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $5.11
Upside: +56.56%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $103.80
Upside: +115.80%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.73
Upside: +998.90%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.61
Upside: +2,675.51%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.14
Upside: +320.56%